Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

eon went from about $3 to $27 on that news. The validation of the manufacturing facility is a critical step to starting this Phase III trial.

Our Phase III trial has been designed to remove many of the common clinical trial problems. We have identified the most common reasons for Phase III study failures or failure to receive approval to sell a drug, other than the drug not working, and they are:

1. Phase III study not reviewed by FDA and not acceptable to FDA:

Our Phase III study was reviewed in detail, and we have made changes

based on FDA's comments prior to commencement of the Phase III

trial.

2. Study too small:

Our study will enroll about 800 patients, a very sizeable number.

3. Clinical endpoint not relevant:

We follow overall survival of the patients, the gold standard. The

Clinical endpoint cannot be more relevant.

4. Change in treatment protocol between Phase II and Phase III without

additional studies:

We have made no such changes. Therefore, we expect the Phase II

results to be representative of the results one can expect in the

Phase III trial.

5. Insufficient attention to manufacturing issues:

We have validated our manufacturing process and built a dedicated

manufacturing facility for Multikine.

We believe that the success of this study will open cancer therapy to a whole new way of fighting cancer, one that is not toxic and one that works with the body, not against the body. We have high confidence that this study will be successful for the following reasons:

  • All clinical indicators support the finding of increased survival in Phase II.
  • The 10% increase in overall survival needed to meet the Phas
    '/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Announces 2008 Financial Results
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 29, 2014 Research and Markets  has ... Gas Analyzer, and Gas Chromatograph Market by Type , ... Global Trends & Forecast to 2013 - 2020" ... analyzer is a process analytical instrument that provides chemical ... redefined the way by which companies carry out their ...
(Date:9/29/2014)... September 29, 2014 Transparency Market Research, ... - SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, ... Generic and by Delivery) - Global Industry Analysis, Size, ... that the global peptide therapeutics market was worth US$14.1 ... billion by 2018 at an 8.7% CAGR. , The ...
(Date:9/29/2014)... Sept. 29, 2014  Atlas Venture, an early stage ... technology innovation, today announced that Jason Rhodes , ... EPZM ), is joining the firm,s life sciences ... At Atlas, Rhodes will work closely with ... brings an accomplished record in company creation, deal making ...
(Date:9/29/2014)... 29, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... Winkley to Chairman of the Board of Directors ... will continue to serve as a Director on the ... Company.  "We are very pleased to ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2SQI Diagnostics Announces New Chairman of Board of Directors 2
... , QIAshredder spin columns are designed for simple and rapid homogenization , of cell and ... , , Format: , ... , , Sample source: ... plant cell or tissue lysates, white blood cell lysates, , ...
... , , , , This ... human cancer-related genes for functional genomics research using , RNAi. ... , , , , ... cancer researchers (see table below for a list of genes). Every siRNA has , ...
... Competent Cells for added , convenience, , , , , , , ... Included , Concentration , , , ... , , , ... 50 ng/l, , , Ligation Master ...
Cached Biology Technology:QIAshredder Homogenizer 2Cancer siRNA Oligo Set Version 1.0 2Cancer siRNA Oligo Set Version 1.0 3Cancer siRNA Oligo Set Version 1.0 4
(Date:9/29/2014)... popular culture, mathematics is often deemed inaccessible or esoteric. ... more important role in our daily lives and a ... ideas often behind the scenes. , UC Santa ... Mathematics and an assistant professor of mechanical engineering, often ... of his recent research published in the Proceedings ...
(Date:9/29/2014)... that a combination of a real-time feedback system together ... residence resulted in a reduction of 37% in energy ... 1360.49 kWh, which is equivalent to a reduction of ... , In contrast, another eight halls, exposed only ... resulted in saw a 3.5% reduction in energy consumption. ...
(Date:9/29/2014)... not normally considered capable of doing anything on their ... move through water. In the future, such moving droplets ... your own to be self-moving is a ... entities can be self-moving, report researchers from University of ... Czech Republic. , The researchers have made alcohol droplets ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Scientists make droplets move on their own 2
... Mellon University President Subra Suresh has been elected a ... the only current university president to be elected to ... is among the highest professional distinctions accorded to engineers, ... those who have made outstanding contributions to their fields. ...
... Medicine of the National Academies honored members Donald Berwick, R. ... today at the IOM,s 43rd annual meeting. ... member for distinguished service over an extended period. He ... Care in America, which produced the landmark reports To Err ...
... The Yangtze finless porpoise, which inhabits the high-traffic waters ... endangered, with only about 1,000 animals alive today. Scientists ... colleagues are using medical technology to shed new light ... waterway punctuated by constant shipping, dredging, and underwater construction. ...
Cached Biology News:Carnegie Mellon President Subra Suresh elected to Institute of Medicine 2Institute of Medicine honors members for outstanding service 2Institute of Medicine honors members for outstanding service 3Seeing in the dark 2Seeing in the dark 3
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
RABBIT ANTI NEOPTERIN...
... Dog serum is collected from fasted mixed breed, ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
Biology Products: